Effect of Treatment with Mucoactive Drugs on COPD Exacerbations During 5 years of Follow-up in the Czech Republic: A Real-World Study

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00179906%3A_____%2F25%3A10498710" target="_blank" >RIV/00179906:_____/25:10498710 - isvavai.cz</a>

Alternative codes found

RIV/00216224:14110/25:00141277 RIV/00216208:11150/25:10498710 RIV/61989592:15110/25:73631965 RIV/00098892:_____/25:10159253

Result on the web

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=qCgX3CAj25" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=qCgX3CAj25</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s00408-025-00813-7" target="_blank" >10.1007/s00408-025-00813-7</a>

Result language

angličtina

Original language name

Effect of Treatment with Mucoactive Drugs on COPD Exacerbations During 5 years of Follow-up in the Czech Republic: A Real-World Study

Original language description

IntroductionStudies indicate that chronic treatment with mucoactive drugs may reduce COPD exacerbation rates. This real-world, multicenter, prospective, observational study aimed to determine the effect of long-term mucoactive treatment on exacerbations in patients with COPD in the Czech Republic.Methods452 adult patients on the Czech Multicenter Research Database of COPD with post-bronchodilator FEV1 &lt;= 60% of predicted value received standard of care and were followed up for 5 years. For the first 24 months, 81 patients received regular thiol-based mucoactive drugs (77 erdosteine, 4 N-acetylcysteine) at the discretion of the treating physician and 371 patients had no mucoactive treatment (control group). Erdosteine was fully reimbursed, and NAC was partially reimbursed for COPD patients. The annual number/rate of COPD exacerbations over 5 years was monitored.ResultsPatients receiving mucoactive treatment for 24 months had a significantly larger reduction from baseline in all exacerbations compared to the control group (- 0.61 vs - 0.18, p = 0.026; - 0.54 vs - 0.09, p = 0.007; - 0.55 vs 0.04, p = 0.005; - 0.67 vs 0.13, p = 0.002; - 0.53 vs 0.10, p = 0.019 in the first to fifth year, respectively). The reduction in moderate exacerbations was also significantly larger in those receiving mucoactive treatment versus no mucoactive treatment. The exacerbation rate was reduced to a greater extent in the subgroups with cough or with stage 3-4 COPD who received mucoactive treatment but was independent of the use of inhaled corticosteroids (ICS).ConclusionMucoactive treatment for two years reduced the number of COPD exacerbations (all, moderate) over five years of follow-up. The reduction in exacerbations was more pronounced in patients with cough or with stage 3-4 COPD but was independent of the use of ICS.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30203 - Respiratory systems

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2025

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Lung

ISSN

0341-2040

e-ISSN

1432-1750

Volume of the periodical

203

Issue of the periodical within the volume

1

Country of publishing house

DE - GERMANY

Number of pages

15

Pages from-to

61

UT code for WoS article

001482949500001

EID of the result in the Scopus database

2-s2.0-105004354643